Tagged with IP,

France From Hungary to Poland and now France, Nienke Feenstra has navigated some of Europe’s most complex healthcare landscapes. Today, as GM of Takeda France, she reflects on the country’s scientific strengths, its vital early access frameworks, and the evolving challenges of sustainability and digital transformation, always with patient value at…

Global Pharma executives are used to navigating complexity, but few periods have tested their judgement like the present. As Brendan Shaw writes, between Washington’s renewed push for “most favoured nation” (MFN) drug pricing, fresh waves of US tariffs, and a volatile global policy mood, the rules of engagement for global pharma…

Global In a pharma industry increasingly squeezed by falling legacy revenues, political pricing crackdowns, and the need to deliver the next wave of science at speed and scale, the right leadership is crucial. Four of the Top 25 global pharma companies – Novo Nordisk (ranked 10th), GSK (12th), Takeda (14th), and…

USA Kendalle O’Connell, President and CEO of MassBio, shares how Massachusetts has built one of the world’s most dynamic life sciences hubs through a mix of bold public investment, targeted programmes, and a “big tent” approach to collaboration. From guiding companies into the right communities with the BioReady programme to fostering…

France Julien Ettersperger, appointed in November 2023 as the first internal leader of Medicen, is steering the agency through a strategic transformation to establish Île-de-France as Europe’s leading health innovation hub. Leveraging the region’s dense research capacity, he champions stronger public-private collaboration to better convert scientific excellence into commercial impact. The…

Denmark Peter Halling, CEO of ALK, leads the century-old allergy immunotherapy innovator through a transformative phase focused on expanding patient access and innovation globally. In this interview, Halling discusses ALK’s Allergy+ growth strategy and response to rising allergy prevalence, unique “field to pharmacy” production model, and ambitions to balance strong European…

Denmark Having become Europe’s number one pharma success story thanks largely to its blockbuster weight-loss drug, Wegovy, Novo Nordisk has been hit with stiff competition from Lilly and seen a steep decline in market performance. The Danish drugmaker has moved to oust its longstanding CEO and is looking to regain lost…

Brazil After a globe-trotting career that led him to diverse global affiliates, the long-term Takeda executive Rodrigo Rodriguez is going full circle. Returning to where he began his career at the Japanese drugmaker, Rodriguez will be taking on a country full of opportunities and challenges. With more dengue cases than anywhere…

Saudi Arabia Leading through transformation requires more than strategic clarity – it demands cultural fluency, consistency of purpose, and the trust of an entire ecosystem. Abed Sabra has spent over 25 years at Roche embodying those principles, guiding the company’s evolution in Saudi Arabia at a time when healthcare is becoming a…

Saudi Arabia Cooper Pharma, with its 90-year legacy, is at the forefront of transforming the pharmaceutical landscape in the Middle East. From localizing production in Saudi Arabia to pioneering collaborations with global institutions, the company is driving innovation in a rapidly evolving market. As Saudi Arabia’s Vision 2030 reshapes the future of…

Saudi Arabia Dr Abdulaziz Alswailem, the CEO of the Saudi Authority for Intellectual Property (SAIP), reflects on the country’s growing role in global intellectual property (IP) policy. He highlights Saudi Arabia’s efforts to foster a strong IP ecosystem through national and international collaborations, such as the Riyadh Design Law Treaty, which sets…

Merck Over the course of its 350-year history, Merck KGaA has expanded from its base in Darmstadt, Germany to establish a strong presence in various markets across the globe. Last year, PharmaBoardroom spoke with Merck affiliate leaders in multiple geographies, uncovering their concerns and priorities as the firm pushed to recover…